XML 30 R19.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summary of Significant Accounting Policies - Segment Information (Details)
3 Months Ended 6 Months Ended
Dec. 31, 2015
USD ($)
Dec. 31, 2014
Dec. 31, 2015
USD ($)
item
Dec. 31, 2014
Segment Information        
Number of operating segments | item     1  
Recent Accounting Pronouncements        
Deferred financing costs $ 5,000,000   $ 5,000,000  
Reduction in long-term assets and Liabilities, current $ 843,000   $ 843,000  
Takeda | Revenues Percentage        
Collaborative Partner:        
Percentages of revenue recognized 49.00%   28.00%  
Novartis | Revenues Percentage        
Collaborative Partner:        
Percentages of revenue recognized 1.00% 54.00% 1.00% 44.00%
Lilly | Revenues Percentage        
Collaborative Partner:        
Percentages of revenue recognized 1.00% 35.00% 16.00% 28.00%
Sanofi | Revenues Percentage        
Collaborative Partner:        
Percentages of revenue recognized 11.00%   6.00% 10.00%
Roche | Revenues Percentage        
Collaborative Partner:        
Percentages of revenue recognized 36.00% 10.00% 37.00% 14.00%